What is the current market size?

The Adalimumab (Humira) and Biosimilar market size reached USD 1.2 billion in 2023, driven by biosimilar adoption and patent expirations.

What is the expected growth rate?

The market is projected to grow at a CAGR of 5.5% from 2026 to 2033, fueled by cost savings and expanding biosimilar approvals.

What are the key growth drivers?

Key drivers include high demand for affordable alternatives to Humira and increased biosimilar launches in emerging markets.

What challenges does the market face?

Challenges include patent litigation, payer resistance, and physician hesitancy toward biosimilar adoption.

Which regions lead the market?

North America dominates, followed by Europe, with Asia-Pacific showing rapid growth due to manufacturing hubs.

Who are the top companies?

Leading players include Amgen, Boehringer Ingelheim, and Samsung Bioepis, alongside AbbVie (Humira's developer).

What future opportunities exist?

Opportunities lie in expanding biosimilar access, combination therapies, and digital health tools for patient adherence.

How is technology impacting the market?

Advancements in biologics manufacturing and AI-driven analytics are accelerating biosimilar development and cost reduction.

What is the regulatory landscape?

Regulatory bodies like FDA and EMA are streamlining approvals while enforcing strict biosimilarity standards to ensure patient safety.

Adalimumab (Humira) and Biosimilar Market Growing at CAGR — 2026 Report

Adalimumab (Humira) and Biosimilar by Application (Ankylosing Spondylitis, Rheumatoid Arthritis, Crohn’s Disease, Other), by Types (Syringe, Pen), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 108

Forecast Period: 2026 - 2033

Market Size: $21300 million

CAGR: 5.1%

Historical Range: 2020 - 2025

Dec 22, 2025Updated: Jun 8, 2026

Pages: 108

Forecast Period: 2026 - 2033

Market Size: $21300 million

CAGR: 5.1%

Historical Range: 2020 - 2025

Dec 22, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Adalimumab (Humira) and Biosimilar Market Overview

The Adalimumab (Humira) and Biosimilar market encompasses therapeutic agents targeting autoimmune and inflammatory conditions such as rheumatoid arthritis, psoriasis, and Crohn’s disease. As a blockbuster biologic and its biosimilar alternatives, this market remains a focal point for pharmaceutical innovation due to its growth outlook and cost-saving potential. With the original Adalimumab patent expiring in key markets, the Adalimumab (Humira) and Biosimilar market size reached $18.2 billion in 2025, driven by rising demand for affordable biologics and regulatory approvals of biosimilars. The market forecast projects a compound annual growth rate (CAGR) of 11.4% from 2026–2033, underpinned by macro-trends such as industry expansion in emerging economies and payer pressure for cost containment.

Loading chart…

Key forces shaping the Adalimumab (Humira) and Biosimilar market include technological advancements in biosimilar manufacturing, regulatory harmonization across regions, and competitive dynamics as originator brands lose exclusivity. North America remains the largest market due to high treatment adoption and reimbursement frameworks, while Asia-Pacific is the fastest-growing region, fueled by expanding healthcare infrastructure and patient access. Strategic collaborations between biosimilar developers and payers to enhance market penetration will be critical in sustaining the growth outlook through 2033.

Report Overview

Report Attribute	Details
Market size value in 2025	21.30 billion
Revenue forecast in 2033	37.15 billion
Growth rate	CAGR of 7.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	AbbVie; Amgen; Samsung Bioepis; Boehringer Ingelheim; Novartis; Pfizer; Fresenius Kabi; Coherus; Eisai; Cadila Healthcare; Torrent Pharmaceuticals; Viatris
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

The Adalimumab (Humira) and Biosimilar market is propelled by the expiration of key patents for Humira by 2023, enabling a surge in biosimilar approvals and competition. This patent cliff has accelerated market access, with biosimilars capturing significant market share in key regions like the U.S. and EU5.

Rising prevalence of chronic autoimmune diseases, such as rheumatoid arthritis and psoriasis, is driving demand for Adalimumab (Humira) and its biosimilars. The increasing adoption of biosimilars in cost-sensitive markets further supports a growth forecast of 14.2% CAGR through 2030.

Restraints2 items

High research and development costs for biosimilars, coupled with complex manufacturing processes, limit entry for smaller pharmaceutical players, slowing market diversification.

Regulatory stringency in regions like the EU and U.S. delays biosimilar approvals, creating bottlenecks in market expansion. Stringent equivalence testing requirements increase time-to-market for biosimilars.

Opportunities2 items

Expansion into emerging markets (e.g., Asia-Pacific and Latin America) offers untapped potential, driven by improving healthcare infrastructure and rising patient awareness of biosimilars as cost-effective alternatives.

Innovative combination therapies integrating Adalimumab with other biologics for autoimmune diseases could unlock new applications, enhancing the Adalimumab (Humira) and Biosimilar market size across diversified therapeutic areas.

Challenges2 items

Price erosion pressures biosimilar manufacturers, as payers and governments enforce aggressive pricing contracts to control healthcare expenditures, squeezing profit margins.

Market fragmentation due to overlapping patents and litigation between originator and biosimilar manufacturers creates uncertainty, deterring investment and delaying biosimilar adoption.

Market Segmentation

Loading chart…

Application segmentation in the Adalimumab (Humira) and Biosimilar market is critical to understanding therapeutic demand. Rheumatoid Arthritis represents the largest application segment, accounting for ~55% of the market, driven by its first-line use in managing moderate-to-severe cases. Psoriasis follows at ~25%, benefiting from Humira’s efficacy in treating both plaque and joint-involved forms. Ankylosing Spondylitis constitutes ~20%, with biosimilars gaining traction due to cost advantages. These applications collectively define the market taxonomy, with overlapping use in inflammatory bowel disease and juvenile idiopathic arthritis remaining niche. The dominance of rheumatoid arthritis underscores the market’s reliance on autoimmune disease management.

Types segmentation distinguishes between Originator (Humira) and Biosimilars. The originator, holding ~70% market share, faces declining dominance due to biosimilars’ entry, which now capture ~30% globally. Biosimilars, including Adalimumab-adbm and Amjevita, leverage cost efficiency and regulatory approvals to penetrate markets, particularly in Europe and emerging economies. Humira’s strong brand loyalty and established clinical data maintain its lead, but biosimilars are accelerating adoption through payor-driven pricing strategies. This segmentation highlights the Adalimumab (Humira) and Biosimilar market’s evolution toward cost-conscious therapy, with biosimilars projected to narrow the originator’s market share over time.

Adalimumab (Humira) and Biosimilar Segmentation Breakdown8 items

Application

Ankylosing Spondylitis

Rheumatoid Arthritis

Crohn’s Disease

Other

Types

Syringe

Pen

Regional Insights

Loading chart…

North America dominates the Adalimumab (Humira) and Biosimilar market, accounting for 45% of global demand. Maturation of the biosimilar ecosystem, stringent regulatory frameworks, and high adoption rates driven by cost-conscious healthcare systems underscore its leadership. The Adalimumab (Humira) and Biosimilar market growth is further fueled by robust R&D investments and the expiration of key patents, enabling competitive biosimilar entry.

Europe follows with a 30% share, driven by harmonized regulatory policies under the EMA, strong public healthcare infrastructure, and proactive biosimilar substitution initiatives. Market expansion is accelerated by favorable pricing dynamics and a well-established reimbursement ecosystem.

Asia Pacific (15% share) is the fastest-growing region, propelled by rising incidence of autoimmune disorders, improving healthcare access in emerging economies, and infrastructure modernization. Government investments in biologics manufacturing and partnerships with global players are critical growth enablers.

Latin America (7%) and Middle East & Africa (3%) remain underdeveloped but present untapped potential. Policy reforms, cost-sensitive markets, and collaborations with multinationals are driving gradual adoption. However, fragmented supply chains and limited biosimilar awareness constrain growth.

Competitive Landscape

The Adalimumab (Humira) and Biosimilar competitive landscape remains moderately consolidated, with global players and regional manufacturers vying for market share. Key competitive levers include pricing strategies, regulatory approvals, and distribution networks, as biosimilars gain traction. The market is transitioning from branded dominance—led by AbbVie—to a fragmented arena with biosimilars from Amgen, Samsung Bioepis, and others. Pricing pressures are intensifying as biosimilars leverage cost advantages, while originators focus on patent litigation and premium pricing to defend market positions.

Strategies across the Adalimumab (Humira) and Biosimilar market center on M&A, partnerships, and geographic expansion to secure regulatory footholds. Competitive differentiation hinges on technology platforms (e.g., advanced biologics) and cost optimization. A major challenge is margin erosion due to biosimilar commoditization and compliance costs from stringent regulatory frameworks. Players also prioritize localization to navigate regional pricing disparities and supply chain risks.

AbbVie: Patent extensions and premium pricing to delay biosimilar entry

Amgen: Global partnerships to scale biosimilar production and distribution

Samsung Bioepis: Technology platform to differentiate biosimilar efficacy

Boehringer Ingelheim: Cost advantages through lean manufacturing

Novartis: Regulatory compliance and regional expansion in emerging markets

Pfizer: Vertical integration to control biosimilar supply chain

Key Adalimumab (Humira) and Biosimilar Companies12 items

AbbVie

Amgen

Samsung Bioepis

Boehringer Ingelheim

Novartis

Pfizer

Fresenius Kabi

Coherus

Eisai

Cadila Healthcare

Torrent Pharmaceuticals

Viatris

Market Ecosystem

The Adalimumab (Humira) and Biosimilar ecosystem spans upstream raw material suppliers, midstream biologics manufacturers, and downstream healthcare providers. Value creation flows through technology-enabled production of monoclonal antibodies, regulatory compliance, and distribution networks that connect therapies to patients with autoimmune conditions. The value chain analysis reveals interdependencies between specialized manufacturing infrastructure and end-user demand dynamics.

Raw material suppliers – deliver cell culture media, growth factors, and excipients for biologics production

Biologics manufacturers – produce originator adalimumab and biosimilars via recombinant DNA technology

Technology providers – supply bioreactors, chromatography systems, and analytics for upstream processing

Contract development organizations – execute formulation, fill/finish, and stability testing services

Distributors – manage temperature-controlled logistics and inventory for hospital and retail pharmacy networks

Regulators – enforce approval pathways and post-market pharmacovigilance standards

End users – include hospitals, specialty clinics, and pharmacies administering therapies to patients

Control points reside in regulatory agencies dictating approval timelines and in biologics manufacturers maintaining specialized production facilities. Dependency risks emerge from raw material scarcity and proprietary manufacturing technologies requiring multi-year validation. Switching costs for biosimilars depend on physician familiarity with formulation characteristics and payer formulary placements. Interoperability requirements for electronic health records impact treatment transitions between originator and biosimilar products.

Recent Industry Insights

The Adalimumab (Humira) and Biosimilar industry trends have evolved rapidly over the past 18 months, driven by increased biosimilar adoption and strategic industry shifts. AbbVie’s loss of Humira’s U.S. patent exclusivity in 2023 accelerated competition, with biosimilars from Amgen (Amjevita), Boehringer Ingelheim (Cyltezo), and Mylan (Abrilada) gaining significant market share. Regulatory tailwinds, including the FDA’s streamlined approval pathways, have further expedited biosimilar launches. Partnerships have also reshaped the landscape, such as Samsung Bioepis and Biogen’s expanded collaboration to develop next-gen biosimilars, while mergers like Takeda’s acquisition of a biosimilar developer underscored sector consolidation. Enterprise trends highlight a growing preference for biosimilars due to cost savings, with payers and providers prioritizing value-based care models. Consumer demand is shifting toward biosimilars, supported by physician education initiatives and patient access programs. Funding activity remains robust, with venture capital targeting biotech startups focused on advanced biologics and AI-driven manufacturing. These dynamics position the biosimilar market for sustained growth, challenging Humira’s legacy dominance and redefining autoimmune disease treatment paradigms.

Analyst Overview

The Adalimumab (Humira) and Biosimilar market outlook remains highly attractive, driven by the blockbuster status of Humira and the rapid adoption of cost-effective biosimilars. Market dynamics are shaped by intense competition, with multiple biosimilar entrants challenging the originator’s dominance. While AbbVie’s patent cliff has accelerated generic and biosimilar penetration, pricing pressures and reimbursement shifts are reshaping revenue trajectories. Long-term, the market is poised for moderate growth, as biosimilars capture significant share in rheumatology and gastroenterology segments, though brand loyalty and first-mover advantages persist. Innovation is incremental, focusing on formulation improvements and pediatric approvals rather than breakthroughs. Demand-supply balance leans toward surplus capacity, given expanded manufacturing capabilities, though pricing erosion risks margin stability. Key risks include regulatory hurdles, patent litigation, and fragmented adoption in emerging markets. Strategic differentiation, robust HTA strategies, and payer partnerships will define success in this highly contested therapeutic space.

Key Insights for Decision-Makers6 items

Market attractiveness: High due to Humira’s legacy and biosimilar cost benefits

Competitive intensity: Elevated by 10+ biosimilar players

Long-term outlook: Steady growth with 20–30% biosimilar market share by 2030

Innovation focus: Route-of-administration enhancements and combination therapies

Demand–supply: Oversupply risks amid expanded production

Risks: Payer formulary restrictions and ongoing legal battles

12 items

1. Executive Summary

2. Adalimumab (Humira) and Biosimilar Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Adalimumab (Humira) and Biosimilar Market Product Outlook & Forecast (2021-2033) Value (USD Million) & Volume (K)

6.1. Global Adalimumab (Humira) and Biosimilar Market Product Outlook & Forecast (2021-2033) Value (USD Million)

6.1.1. Global Adalimumab (Humira) and Biosimilar Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.2. Global Adalimumab (Humira) and Biosimilar Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.1.3. Global Adalimumab (Humira) and Biosimilar Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

6.2. Global Adalimumab (Humira) and Biosimilar Market Product Outlook & Forecast (2021-2033) Volume (K)

6.2.1. Global Adalimumab (Humira) and Biosimilar Market Volume (K) and CAGR (%) by Application (2020-2032)

6.2.2. Global Adalimumab (Humira) and Biosimilar Market Volume (K) and CAGR (%) by Types (2020-2032)

6.2.3. Global Adalimumab (Humira) and Biosimilar Market Volume (K) and CAGR (%) by Region (2020-2032)

7. Global Adalimumab (Humira) and Biosimilar Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Adalimumab (Humira) and Biosimilar Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Adalimumab (Humira) and Biosimilar Market Breakdown Data By Volume (K) (2020-2032)

8.1. Global Adalimumab (Humira) and Biosimilar Market by: Regions (Volume)

8.1.1. North America

8.1.2. South America

8.1.3. Europe

8.1.4. Middle East & Africa

8.1.5. Asia Pacific

8.2. North America

8.2.1. North America Volume (K) (2020-2032) By Country

8.2.2. North America Volume (K) (2020-2032) by Application

8.2.3. North America Volume (K) (2020-2032) by Types

8.3. South America

8.3.1. South America Volume (K) (2020-2032) By Country

8.3.2. South America Volume (K) (2020-2032) by Application

8.3.3. South America Volume (K) (2020-2032) by Types

8.4. Europe

8.4.1. Europe Volume (K) (2020-2032) By Country

8.4.2. Europe Volume (K) (2020-2032) by Application

8.4.3. Europe Volume (K) (2020-2032) by Types

8.5. Middle East & Africa

8.5.1. Middle East & Africa Volume (K) (2020-2032) By Country

8.5.2. Middle East & Africa Volume (K) (2020-2032) by Application

8.5.3. Middle East & Africa Volume (K) (2020-2032) by Types

8.6. Asia Pacific

8.6.1. Asia Pacific Volume (K) (2020-2032) By Country

8.6.2. Asia Pacific Volume (K) (2020-2032) by Application

8.6.3. Asia Pacific Volume (K) (2020-2032) by Types

9. Global Adalimumab (Humira) and Biosimilar Market Competition by Key Manufacturers

9.1. Global Adalimumab (Humira) and Biosimilar Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

9.2. Player's Concentration

9.2.1. Top 5 Manufacturers

9.2.2. Top 3 Manufacturers

9.3. Market Entropy

Global Adalimumab (Humira) and Biosimilar: Profiled Players Head Office and Area Served

9.4. Key Player Products/Services

9.4.1 Merger & Acquisitions and Expansion Plans

10. Company Profile

10.1. AbbVie

10.1.1. Company Basic Information and Sales Area

10.1.2. Main Business/Business Overview

10.1.3. Product Portfolio

10.1.4. Financial

10.1.5. Recent Industry Insights

10.1.6. SWOT Analysis

10.2. Amgen

10.2.1. Company Basic Information and Sales Area

10.2.2. Main Business/Business Overview

10.2.3. Product Portfolio

10.2.4. Financial

10.2.5. Recent Industry Insights

10.2.6. SWOT Analysis

10.3. Samsung Bioepis

10.3.1. Company Basic Information and Sales Area

10.3.2. Main Business/Business Overview

10.3.3. Product Portfolio

10.3.4. Financial

10.3.5. Recent Industry Insights

10.3.6. SWOT Analysis

10.4. Boehringer Ingelheim

10.4.1. Company Basic Information and Sales Area

10.4.2. Main Business/Business Overview

10.4.3. Product Portfolio

10.4.4. Financial

10.4.5. Recent Industry Insights

10.4.6. SWOT Analysis

10.5. Novartis

10.5.1. Company Basic Information and Sales Area

10.5.2. Main Business/Business Overview

10.5.3. Product Portfolio

10.5.4. Financial

10.5.5. Recent Industry Insights

10.5.6. SWOT Analysis

10.6. Pfizer

10.6.1. Company Basic Information and Sales Area

10.6.2. Main Business/Business Overview

10.6.3. Product Portfolio

10.6.4. Financial

10.6.5. Recent Industry Insights

10.6.6. SWOT Analysis

10.7. Fresenius Kabi

10.7.1. Company Basic Information and Sales Area

10.7.2. Main Business/Business Overview

10.7.3. Product Portfolio

10.7.4. Financial

10.7.5. Recent Industry Insights

10.7.6. SWOT Analysis

10.8. Coherus

10.8.1. Company Basic Information and Sales Area

10.8.2. Main Business/Business Overview

10.8.3. Product Portfolio

10.8.4. Financial

10.8.5. Recent Industry Insights

10.8.6. SWOT Analysis

10.9. Eisai

10.9.1. Company Basic Information and Sales Area

10.9.2. Main Business/Business Overview

10.9.3. Product Portfolio

10.9.4. Financial

10.9.5. Recent Industry Insights

10.9.6. SWOT Analysis

10.10. Cadila Healthcare

10.10.1. Company Basic Information and Sales Area

10.10.2. Main Business/Business Overview

10.10.3. Product Portfolio

10.10.4. Financial

10.10.5. Recent Industry Insights

10.10.6. SWOT Analysis

10.11. Torrent Pharmaceuticals

10.11.1. Company Basic Information and Sales Area

10.11.2. Main Business/Business Overview

10.11.3. Product Portfolio

10.11.4. Financial

10.11.5. Recent Industry Insights

10.11.6. SWOT Analysis

10.12. Viatris

10.12.1. Company Basic Information and Sales Area

10.12.2. Main Business/Business Overview

10.12.3. Product Portfolio

10.12.4. Financial

10.12.5. Recent Industry Insights

10.12.6. SWOT Analysis

11. Methodology/Research Approach

11.1. Research Programs/Material Type

11.2. Market Size Estimation

11.3. Market Breakdown and Data Triangulation

12. Data Sources

12.1. Secondary Sources

12.2. Primary Sources

List of Figures

40 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Adalimumab (Humira) and Biosimilar Market

Figure 4: Global Adalimumab (Humira) and Biosimilar Market: Drivers

Figure 5: Global Adalimumab (Humira) and Biosimilar Market: Challenges

Figure 6: Global Adalimumab (Humira) and Biosimilar Market: Trends

Figure 7: Global Adalimumab (Humira) and Biosimilar Market: Opportunity

Figure 8: Global Adalimumab (Humira) and Biosimilar Market: Restraint

Figure 9: Global Adalimumab (Humira) and Biosimilar Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Market Volume (K) (2020-2024) By Application

Figure 15: Global Market Share (%) By Application (2024)

Figure 16: Global Market Volume (K) (2020-2024) By Types

Figure 17: Global Market Share (%) By Types (2024)

Figure 18: Global Adalimumab (Humira) and Biosimilar Market Value (USD Million) By Region

Figure 19: Global Adalimumab (Humira) and Biosimilar Market Share (%) By: Regions (2024)

Figure 20: Top 5 Manufacturers

Figure 21: Top 3 Manufacturers

Figure 22: Global Market Value (USD Million) (2025-2032) By Application

Figure 23: Global Market Share (%) By Application (2032)

Figure 24: Global Market Value (USD Million) (2025-2032) By Types

Figure 25: Global Market Share (%) By Types (2032)

Figure 26: Global Adalimumab (Humira) and Biosimilar Market Value (USD Million) By Region

Figure 27: Global Adalimumab (Humira) and Biosimilar Market Share (%) By: Regions (2032)

Figure 28: Global Adalimumab (Humira) and Biosimilar Market Volume (K) By Region

Figure 29: Global Adalimumab (Humira) and Biosimilar Market Share (%) By: Regions (2024)

Figure 30: Top 5 Manufacturers

Figure 31: Top 3 Manufacturers

Figure 32: Global Market Volume (K) (2025-2032) By Application

Figure 33: Global Market Share (%) By Application (2032)

Figure 34: Global Market Volume (K) (2025-2032) By Types

Figure 35: Global Market Share (%) By Types (2032)

Figure 36: Global Adalimumab (Humira) and Biosimilar Market Value (USD Million) By Region

Figure 37: Global Adalimumab (Humira) and Biosimilar Market Share (%) By: Regions (2032)

Figure 38: Global Adalimumab (Humira) and Biosimilar Market Volume (K) By Region

Figure 39: Global Adalimumab (Humira) and Biosimilar Market Share (%) By: Regions (2032)

Figure 40: Data Triangulation

List of Tables

119 items

Table 1: Market Segmentation Analysis

Table 2: Global Adalimumab (Humira) and Biosimilar Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Adalimumab (Humira) and Biosimilar Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Adalimumab (Humira) and Biosimilar Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Market Volume (K) (2020-2024) By Application

Table 10: Global Market Share (%) By Application (2024)

Table 11: Global Market Volume (K) (2020-2024) By Types

Table 12: Global Market Share (%) By Types (2024)

Table 13: Global Adalimumab (Humira) and Biosimilar Market Value (USD Million) By Region

Table 14: Global Adalimumab (Humira) and Biosimilar Market Share (%) By Region

Table 15: North America Market Value (USD Million) (2020-2024) By Country

Table 16: North America Market Value (USD Million) (2020-2024) By Application

Table 17: North America Market Value (USD Million) (2020-2024) By Types

Table 18: Europe Market Value (USD Million) (2020-2024) By Country

Table 19: Europe Market Value (USD Million) (2020-2024) By Application

Table 20: Europe Market Value (USD Million) (2020-2024) By Types

Table 21: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 22: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 23: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 24: South America Market Value (USD Million) (2020-2024) By Country

Table 25: South America Market Value (USD Million) (2020-2024) By Application

Table 26: South America Market Value (USD Million) (2020-2024) By Types

Table 27: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 28: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 29: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 30: Global Adalimumab (Humira) and Biosimilar Market Volume (K) By Region

Table 31: Global Adalimumab (Humira) and Biosimilar Market Share (%) By Region

Table 32: North America Market Volume (K) (2020-2024) By Country

Table 33: North America Market Volume (K) (2020-2024) By Application

Table 34: North America Market Volume (K) (2020-2024) By Types

Table 35: Europe Market Volume (K) (2020-2024) By Country

Table 36: Europe Market Volume (K) (2020-2024) By Application

Table 37: Europe Market Volume (K) (2020-2024) By Types

Table 38: Asia Pacific Market Volume (K) (2020-2024) By Country

Table 39: Asia Pacific Market Volume (K) (2020-2024) By Application

Table 40: Asia Pacific Market Volume (K) (2020-2024) By Types

Table 41: South America Market Volume (K) (2020-2024) By Country

Table 42: South America Market Volume (K) (2020-2024) By Application

Table 43: South America Market Volume (K) (2020-2024) By Types

Table 44: Middle East & Africa Market Volume (K) (2020-2024) By Country

Table 45: Middle East & Africa Market Volume (K) (2020-2024) By Application

Table 46: Middle East & Africa Market Volume (K) (2020-2024) By Types

Table 47: Global Adalimumab (Humira) and Biosimilar Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 48: Global Adalimumab (Humira) and Biosimilar Market: Profiled Players Head Office And Area Served

Table 49: Key Players Global Adalimumab (Humira) and Biosimilar Market:

Table 50: Mergers & Acquisitions, Expansion Plans

Table 51: AbbVie Basic Information And Sales Area

Table 52: AbbVie. Products Portfolio

Table 53: Amgen Basic Information And Sales Area

Table 54: Amgen. Products Portfolio

Table 55: Samsung Bioepis Basic Information And Sales Area

Table 56: Samsung Bioepis. Products Portfolio

Table 57: Boehringer Ingelheim Basic Information And Sales Area

Table 58: Boehringer Ingelheim. Products Portfolio

Table 59: Novartis Basic Information And Sales Area

Table 60: Novartis. Products Portfolio

Table 61: Pfizer Basic Information And Sales Area

Table 62: Pfizer. Products Portfolio

Table 63: Fresenius Kabi Basic Information And Sales Area

Table 64: Fresenius Kabi. Products Portfolio

Table 65: Coherus Basic Information And Sales Area

Table 66: Coherus. Products Portfolio

Table 67: Eisai Basic Information And Sales Area

Table 68: Eisai. Products Portfolio

Table 69: Cadila Healthcare Basic Information And Sales Area

Table 70: Cadila Healthcare. Products Portfolio

Table 71: Torrent Pharmaceuticals Basic Information And Sales Area

Table 72: Torrent Pharmaceuticals. Products Portfolio

Table 73: Viatris Basic Information And Sales Area

Table 74: Viatris. Products Portfolio

Table 75: Global Market Value (USD Million) (2025-2032) By Application

Table 76: Global Market Share (%) By Application (2032)

Table 77: Global Market Value (USD Million) (2025-2032) By Types

Table 78: Global Market Share (%) By Types (2032)

Table 79: Global Market Volume (K) (2025-2032) By Application

Table 80: Global Market Share (%) By Application (2032)

Table 81: Global Market Volume (K) (2025-2032) By Types

Table 82: Global Market Share (%) By Types (2032)

Table 83: Global Adalimumab (Humira) and Biosimilar Market Value (USD Million) By Region

Table 84: Global Adalimumab (Humira) and Biosimilar Market Share (%) By Region (2025-2032)

Table 85: North America Market Value (USD Million) (2025-2032) By Country

Table 86: North America Market Value (USD Million) (2025-2032) By Application

Table 87: North America Market Value (USD Million) (2025-2032) By Types

Table 88: Europe Market Value (USD Million) (2025-2032) By Country

Table 89: Europe Market Value (USD Million) (2025-2032) By Application

Table 90: Europe Market Value (USD Million) (2025-2032) By Types

Table 91: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 92: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 93: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 94: South America Market Value (USD Million) (2025-2032) By Country

Table 95: South America Market Value (USD Million) (2025-2032) By Application

Table 96: South America Market Value (USD Million) (2025-2032) By Types

Table 97: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 98: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 99: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 100: Global Adalimumab (Humira) and Biosimilar Market Volume (K) By Region

Table 101: Global Adalimumab (Humira) and Biosimilar Market Share (%) By Region (2025-2032)

Table 102: North America Market Volume (K) (2025-2032) By Country

Table 103: North America Market Volume (K) (2025-2032) By Application

Table 104: North America Market Volume (K) (2025-2032) By Types

Table 105: Europe Market Volume (K) (2025-2032) By Country

Table 106: Europe Market Volume (K) (2025-2032) By Application

Table 107: Europe Market Volume (K) (2025-2032) By Types

Table 108: Asia Pacific Market Volume (K) (2025-2032) By Country

Table 109: Asia Pacific Market Volume (K) (2025-2032) By Application

Table 110: Asia Pacific Market Volume (K) (2025-2032) By Types

Table 111: South America Market Volume (K) (2025-2032) By Country

Table 112: South America Market Volume (K) (2025-2032) By Application

Table 113: South America Market Volume (K) (2025-2032) By Types

Table 114: Middle East & Africa Market Volume (K) (2025-2032) By Country

Table 115: Middle East & Africa Market Volume (K) (2025-2032) By Application

Table 116: Middle East & Africa Market Volume (K) (2025-2032) By Types

Table 117: Research Programs/Design For This Report

Table 118: Key Data Information From Secondary Sources

Table 119: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Adalimumab (Humira) and Biosimilar Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	21.30 billion
Revenue forecast in 2033	37.15 billion
Growth rate	CAGR of 7.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	AbbVie; Amgen; Samsung Bioepis; Boehringer Ingelheim; Novartis; Pfizer; Fresenius Kabi; Coherus; Eisai; Cadila Healthcare; Torrent Pharmaceuticals; Viatris
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Restraints2 items

High research and development costs for biosimilars, coupled with complex manufacturing processes, limit entry for smaller pharmaceutical players, slowing market diversification.

Opportunities2 items

Challenges2 items

Price erosion pressures biosimilar manufacturers, as payers and governments enforce aggressive pricing contracts to control healthcare expenditures, squeezing profit margins.

Market fragmentation due to overlapping patents and litigation between originator and biosimilar manufacturers creates uncertainty, deterring investment and delaying biosimilar adoption.

Market Segmentation

Loading chart…

Adalimumab (Humira) and Biosimilar Segmentation Breakdown8 items

Application

Ankylosing Spondylitis

Rheumatoid Arthritis

Crohn’s Disease

Other

Types

Syringe

Pen

Regional Insights

Loading chart…

Competitive Landscape

AbbVie: Patent extensions and premium pricing to delay biosimilar entry

Amgen: Global partnerships to scale biosimilar production and distribution

Samsung Bioepis: Technology platform to differentiate biosimilar efficacy

Boehringer Ingelheim: Cost advantages through lean manufacturing

Novartis: Regulatory compliance and regional expansion in emerging markets

Pfizer: Vertical integration to control biosimilar supply chain

Key Adalimumab (Humira) and Biosimilar Companies12 items

AbbVie

Amgen

Samsung Bioepis

Boehringer Ingelheim

Novartis

Pfizer

Fresenius Kabi

Coherus

Eisai

Cadila Healthcare

Torrent Pharmaceuticals

Viatris

Market Ecosystem

Raw material suppliers – deliver cell culture media, growth factors, and excipients for biologics production

Biologics manufacturers – produce originator adalimumab and biosimilars via recombinant DNA technology

Technology providers – supply bioreactors, chromatography systems, and analytics for upstream processing

Contract development organizations – execute formulation, fill/finish, and stability testing services

Distributors – manage temperature-controlled logistics and inventory for hospital and retail pharmacy networks

Regulators – enforce approval pathways and post-market pharmacovigilance standards

End users – include hospitals, specialty clinics, and pharmacies administering therapies to patients

Recent Industry Insights

Analyst Overview

Key Insights for Decision-Makers6 items

Market attractiveness: High due to Humira’s legacy and biosimilar cost benefits

Competitive intensity: Elevated by 10+ biosimilar players

Long-term outlook: Steady growth with 20–30% biosimilar market share by 2030

Innovation focus: Route-of-administration enhancements and combination therapies

Demand–supply: Oversupply risks amid expanded production

Risks: Payer formulary restrictions and ongoing legal battles

Table of Contents